AYA.AX stock up 1.24% on ASX as Artrya Limited gains intraday

Artrya Limited (AYA.AX) climbed 1.24% to A$4.08 on the ASX during intraday trading on 27 April 2026. The healthcare AI company, which develops coronary artery disease detection software, showed positive momentum as trading volume reached 28,162 shares. AYA.AX stock has recovered from its year low of A$0.58, now trading closer to its 50-day average of A$3.37. The company’s market cap stands at A$463.17 million. Meyka AI’s analysis platform tracks real-time price movements and technical indicators for investors monitoring this medical technology play on the Australian exchange.

AYA.AX Stock Performance and Price Action

Artrya Limited’s AYA.AX stock opened at A$4.08 with a day range between A$4.00 and A$4.11. The 0.05 AUD gain represents solid intraday strength for the healthcare AI company. Year-to-date, AYA.AX stock has declined 13.59%, reflecting broader market headwinds in the healthcare sector. However, the one-month performance shows impressive 50.74% gains, suggesting recent investor interest in the company’s AI-driven coronary detection platform.

The stock’s 52-week range spans from A$0.58 to A$5.24, demonstrating significant volatility typical of early-stage medical technology companies. Trading volume of 28,162 shares remains below the average volume of 487,885, indicating lighter activity today. Track AYA.AX on Meyka for real-time updates on price movements and technical analysis.

Technical Indicators and Market Sentiment

AYA.AX stock displays mixed technical signals with an RSI of 56.96, suggesting neutral momentum without overbought conditions. The MACD shows positive divergence with a histogram value of 0.03, indicating potential upside momentum. The ADX reading of 29.45 confirms a strong trend is developing in the stock’s price action.

Volatility indicators reveal Bollinger Bands ranging from A$2.87 to A$4.63, with the stock trading near the middle band at A$3.75. The Stochastic indicator (%K: 63.12, %D: 71.80) suggests the stock may be approaching overbought territory. Money Flow Index at 61.65 shows strong buying pressure, while the Rate of Change at 30.03% reflects recent upward momentum in AYA.AX stock price action.

Financial Metrics and Valuation Concerns

Artrya Limited faces significant profitability challenges reflected in its financial metrics. The company reports negative earnings per share of -A$0.17 with a PE ratio of -23.94, indicating ongoing losses. Net profit margin stands at -679.59%, showing the company burns cash while generating minimal revenue. Return on equity is deeply negative at -35.63%, and return on assets at -21.38%.

The price-to-book ratio of 5.73 appears elevated given the negative profitability metrics. However, the current ratio of 37.11 demonstrates exceptional liquidity, with cash per share at A$0.61. Meyka AI rates AYA.AX with a grade of B, suggesting a HOLD recommendation. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.

Price Forecasts and Growth Outlook

Meyka AI’s forecast model projects AYA.AX stock reaching A$7.41 within one year, implying 81.6% upside from current levels. The three-year forecast suggests A$14.93, while the five-year projection reaches A$22.43. These forecasts are model-based projections and not guarantees. The company’s research and development spending represents 84.34% of revenue, reflecting heavy investment in AI technology development.

Artrya Limited operates Salix, a cloud-based software platform using artificial intelligence to automate coronary artery disease detection. With 430 full-time employees and headquarters in West Perth, Australia, the company targets the growing medical technology sector. The earnings announcement is scheduled for 27 August 2026, which may provide clarity on commercialization progress and cash burn rates.

Final Thoughts

Artrya Limited’s AYA.AX stock gained 1.24% to A$4.08, showing positive technical momentum despite negative profitability. Strong liquidity and a B-grade rating suggest potential, but year-to-date losses of 13.59% highlight volatility. Patient investors should monitor the company until the August earnings announcement provides concrete evidence of AI commercialization progress and reduced cash burn.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.